invIOs secures €8.2m Series A funding, collaborates with Dana-Farber, and plans clinical studies for INV441 in 2025.

invIOs, a biotech firm specializing in cancer therapies, has secured €8.2 million in Series A funding to advance its research and clinical development through 2025. The company is collaborating with the Dana-Farber Cancer Institute on two key programs: INV441, a cell therapy using modified tumor-infiltrating lymphocytes, and INV501, an oral small molecule enhancing T cell responses. Clinical studies for INV441 are expected to begin in mid-2025.

October 15, 2024
5 Articles